Sprouts Farmers Market closes $600 million revolving credit facility
On Tuesday, Leerink Partners analysts reiterated their Outperform rating and maintained a $23.00 price target on Kura Oncology (NASDAQ: NASDAQ:KURA) stock, representing significant upside from the current price of $6.30. According to InvestingPro data, analysts’ targets range from $8 to $40, with a strong Buy consensus. This follows the full presentation of the KOMET-001 data at the American Society of Clinical Oncology (ASCO) Annual Meeting, which aligned with previous results disclosed in an abstract.
Kura Oncology also announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ziftomenib, a treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML), and granted it priority review. The Prescription Drug User Fee Act (PDUFA) date is set for November 30, 2025. The company maintains a strong financial position with a healthy current ratio of 8.07 and more cash than debt on its balance sheet, providing runway for its development programs.
The recent data presentation at ASCO provided additional insights into overall survival and transfusion independence conversion, reinforcing ziftomenib’s favorable benefit-risk profile. Kura Oncology hosted an investor event to address key questions regarding upcoming data updates and future milestones for ziftomenib. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which covers what really matters for investors in Kura Oncology.
The company is also preparing for the release of updated Phase Ib dose expansion data from the KOMET-007 study, which combines ziftomenib with intensive chemotherapy for first-line AML treatment. This data will be presented at the European Hematology Association (EHA) Congress on June 12, 2025.
Leerink Partners views these developments as positive steps in Kura Oncology’s strategic plan for ziftomenib and its farnesyltransferase inhibitor programs, positioning the company for potential long-term success.
In other recent news, Kura Oncology reported a significant increase in revenue for the first quarter of 2025, reaching $14.1 million compared to zero in the same period last year. Despite this revenue boost, the company missed earnings per share estimates, reporting -$0.66 against a forecast of -$0.62. Kura Oncology’s cash position remains robust, expected to support operations into 2027. Additionally, the company, in partnership with Kyowa Kirin, announced positive results from the Phase 2 KOMET-001 trial for ziftomenib, a treatment for relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). The trial showed a complete remission rate of 23% among 92 patients, with a favorable safety profile. Analysts from Cantor Fitzgerald and H.C. Wainwright have reiterated positive ratings for Kura Oncology, highlighting the potential of ziftomenib as a significant development in AML treatment. The FDA has accepted the New Drug Application for ziftomenib, granting it Priority Review with a target action date of November 30, 2025. These developments underscore Kura Oncology’s ongoing efforts to advance its pipeline and address unmet medical needs in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.